Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate.
Abiraterone acetate
Adverse events
D4A
Polymorphisms
Prostate cancer
Trough concentration
Journal
European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
24
09
2022
accepted:
05
11
2022
pubmed:
16
11
2022
medline:
10
1
2023
entrez:
15
11
2022
Statut:
ppublish
Résumé
We assessed the impact of plasma trough concentrations of abiraterone (ABI) and its metabolite Δ4-abiraterone (D4A) and related polymorphisms on adverse events (AEs) in patients with metastatic prostate cancer who received abiraterone acetate (AA). This prospective study enrolled patients with advanced prostate cancer treated with AA between 2016 and 2021. Plasma trough concentrations of ABI and D4A were measured using high-performance liquid chromatography. The impact of HSD3B1 rs1047303, SRD5A2 rs523349, and cytochrome P450 family 3A member 4 rs2242480 polymorphisms on plasma concentrations of ABI and D4A and the incidence of AEs were also assessed. In 68 patients treated with AA, the median ABI and D4A concentrations were 18.1 and 0.94 ng/mL, respectively. The high plasma trough concentration of ABI (≥ 20.6 ng/mL) was significantly associated with the presence of any AE and its independent risk factor based on multivariable analysis (odds ratio, 7.20; 95% confidence interval (CI): 2.20-23.49). Additionally, a high plasma trough concentration of ABI was an independent risk factor of time to withdraw AA (hazard ratio, 4.89; 95% CI: 1.66-14.38). The risk alleles of three polymorphisms were not statistically associated with the ABI and D4A concentrations and the incidence of AEs. The plasma trough concentration of ABI is associated with the presence of AEs and treatment failure after AA administration. ABI concentration monitoring may be useful in patients with prostate cancer who received AA.
Identifiants
pubmed: 36378297
doi: 10.1007/s00228-022-03420-0
pii: 10.1007/s00228-022-03420-0
doi:
Substances chimiques
Abiraterone Acetate
EM5OCB9YJ6
abiraterone
G819A456D0
Androstenes
0
SRD5A2 protein, human
EC 1.3.99.5
Membrane Proteins
0
3-Oxo-5-alpha-Steroid 4-Dehydrogenase
EC 1.3.99.5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
89-98Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Stuyckens K, Saad F, Xu XS, Ryan CJ, Smith MR, Griffin TW, Yu MK, Vermeulen A, Nandy P, Poggesi I (2014) Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet 53(12):1149–1160. https://doi.org/10.1007/s40262-014-0178-6
doi: 10.1007/s40262-014-0178-6
Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983–992. https://doi.org/10.1016/S1470-2045(12)70379-0
doi: 10.1016/S1470-2045(12)70379-0
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352–360. https://doi.org/10.1056/NEJMoa1704174
doi: 10.1056/NEJMoa1704174
Miller K, Carles J, Gschwend JE, Van Poppel H, Diels J, Brookman-May SD (2018) The phase 3 COU-AA-302 study of abiraterone acetate plus prednisone in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: stratified analysis based on pain, prostate-specific antigen, and Gleason score. Eur Urol 74(1):17–23. https://doi.org/10.1016/j.eururo.2017.08.035
doi: 10.1016/j.eururo.2017.08.035
Alyamani M, Emamekhoo H, Park S, Taylor J, Almassi N, Upadhyay S et al (2018) HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. J Clin Invest 128(8):3333–3340. https://doi.org/10.1172/JCI98319
doi: 10.1172/JCI98319
Li Z, Bishop AC, Alyamani M, Garcia JA, Dreicer R, Bunch D, Liu J, Upadhyay SK, Auchus RJ, Sharifi N (2015) Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature 523(7560):347–351. https://doi.org/10.1038/nature14406
doi: 10.1038/nature14406
Shiota M, Akamatsu S, Narita S, Sumiyoshi T, Fujiwara M, Uchiumi T, Ogawa O, Habuchi T, Eto M (2021) The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer. Pharmacogenomics J 21(4):440–445. https://doi.org/10.1038/s41397-021-00220-0
doi: 10.1038/s41397-021-00220-0
Benoist GE, van der Doelen MJ, Ter Heine R, van Erp NP, Mehra N (2018) A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration-resistant metastatic prostate cancer. Br J Clin Pharmacol 84(5):1064–1067. https://doi.org/10.1111/bcp.13532
doi: 10.1111/bcp.13532
Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R, Jaehde U, Steeghs N, Huitema ADR, Kloft C (2021) Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol 77(4):441–464. https://doi.org/10.1007/s00228-020-03014-8
doi: 10.1007/s00228-020-03014-8
van Nuland M, Groenland SL, Bergman AM, Steeghs N, Rosing H, Venekamp N, Huitema ADR, Beijnen JH (2020) Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 23(2):244–251. https://doi.org/10.1038/s41391-019-0179-5
doi: 10.1038/s41391-019-0179-5
Carton E, Noe G, Huillard O, Golmard L, Giroux J, Cessot A, Saidu NEB, Peyromaure M, Zerbib M, Narjoz C, Guibourdenche J, Thomas A, Vidal M, Goldwasser F, Blanchet B, Alexandre J (2017) Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. Eur J Cancer 72:54–61. https://doi.org/10.1016/j.ejca.2016.11.027
doi: 10.1016/j.ejca.2016.11.027
Miura M, Satoh S, Kagaya H, Saito M, Numakura K, Tsuchiya N, Habuchi T (2011) Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics 12(7):977–984. https://doi.org/10.2217/pgs.11.33
doi: 10.2217/pgs.11.33
Narita S, Tsuchiya N, Kumazawa T, Maita S, Numakura K, Obara T, Tsuruta H, Inoue T, Horikawa Y, Satoh S, Nanjyo H, Habuchi T (2012) Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. World J Surg Oncol 10:1. https://doi.org/10.1186/1477-7819-10-1
doi: 10.1186/1477-7819-10-1
Hu YF, Tu JH, Tan ZR, Liu ZQ, Zhou G, He J, Wang D, Zhou HH (2007) Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica 37(3):315–327. https://doi.org/10.1080/00498250601149206
doi: 10.1080/00498250601149206
Ozeki T, Nagahama M, Fujita K, Suzuki A, Sugino K, Ito K, Miura M (2019) Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Sci Rep 9(1):5404. https://doi.org/10.1038/s41598-019-41820-y
doi: 10.1038/s41598-019-41820-y
Benoist GE, Hendriks RJ, Mulders PF, Gerritsen WR, Somford DM, Schalken JA, van Oort IM, Burger DM, can Erp NP, (2016) Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide. Clin Pharmacokinet 55(11):1369–1380. https://doi.org/10.1007/s40262-016-0403-6
doi: 10.1007/s40262-016-0403-6
Matsubara N, Uemura H, Satoh T, Suzuki H, Nishiyama T, Uemura H, Hashine K, Imanaka K, Ozono S, Akaza, (2014) A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study). Jpn J Clin Oncol 44(12):1216–1226. https://doi.org/10.1093/jjco/hyu149
doi: 10.1093/jjco/hyu149
Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harbey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ (2018) Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol 36(14):1389–1395. https://doi.org/10.1200/JCO.2017.76.4381
doi: 10.1200/JCO.2017.76.4381
Alyamani M, Li Z, Upadhyay SK, Anderson DJ, Auchus RJ, Sharifi N (2017) Development and validation of a novel LC-MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column. J Steroid Biochem Mol Biol 172:231–239. https://doi.org/10.1016/j.jsbmb.2016.04.002
doi: 10.1016/j.jsbmb.2016.04.002